Efficacy of chemotherapy as a first-line treatment in patients with ocular adnexal MALT lymphoma.
- Author:
Feng NING
1
;
Jin YE
;
Li-Qiang WEI
;
Xin LI
;
Jing-Wen WANG
Author Information
1. Department of Hematology, Capital University of Medical Sciences, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Eye Neoplasms;
drug therapy;
Female;
Humans;
Lymphoma, B-Cell, Marginal Zone;
drug therapy;
Male;
Middle Aged
- From:
Journal of Experimental Hematology
2012;20(4):912-916
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to analyze the efficacy of first-line chemotherapy in treating patients with ocular adnexal extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT). Eight consecutive newly diagnosed ocular adnexal MALT lymphoma patients were treated with chemotherapy, in which 3 patients in stage IE were treated with a combination of cyclophosphamide, vincristine and prednisolone (COP) or cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP), 5 patients in stage IV were treated with COP/CHOP in combination with rituximab. The results showed that chemotherapy resulted in an overall response rate of 100%, 3 patients in stage IE were in partial remission (PR), 5 patients in stage IV were in complete remission (CR). After a median follow-up of 21 months, 3 patients in stage IE were still in PR status, 5 patients in stage IV were still in CR status, and no relapses or disease progression were observed. It is concluded that the first-line chemotherapy has been confirmed to be effective and well tolerated in patients with localized ocular adnexal MALT lymphoma. Rituximab combined with chemotherapy can increase remission rate, it is feasible option as first-line treatment for ocular adnexal MALT lymphoma.
